PropertyValue
?:abstract
  • A novel coronavirus disease, COVID-19, has emerged as a global public health issue. Clinical course of disease significantly correlates with the occurrence of some comorbidities, among them type 2 diabetes. According to recent structural studies the dipeptidyl peptidase 4, a key molecule in the pathophysiology of diabetes, may influence the course of COVID-19. Since DPP4 inhibitors, gliptins, are widely used in diabetes patients, the exact role of DPP4 modulation in SARS-CoV-2 infection, at least in that group, urgently needs to be clarified. In this short review, we discuss this issue with more detail.
?:creator
?:journal
  • Arch_Immunol_Ther_Exp_(Warsz)
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • DPP4 Inhibitors and COVID-19-Holy Grail or Another Dead End?
?:type
?:who_covidence_id
  • #1059377
  • #1059378
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/7i58lsx8>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/7i58lsx8>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all